We're anticipating FDA decisions for tildrakizumab, obinutuzumab, and more, including a potential first targeted therapy for Sjögren's disease.
News|Articles|July 8, 2026
First Half 2026 Rheumatology Recap
Author(s)RheumatologyLive Editorial Staff
Fact checked by: Victoria Johnson
We reviewed new psoriatic arthritis approvals as well as data readouts from head-to-head trials and milestone data in IgG4-related disease.
Advertisement
Advertisement
The first half of 2026 was among the most consequential half-years in rheumatology in recent memory, defined by a first-in-class oral approval, landmark head-to-head data, a major EULAR readout season, 2 significant guideline updates, and a string of regulatory filings that set up an eventful second half. The most significant regulatory story of the half was the March approval of deucravacitinib for psoriatic arthritis (PsA) — the first TYK2 inhibitor indicated for PsA, expanding a class already established in plaque psoriasis.
Related to this article
Amgen reported dazodalibep met its primary endpoint in the phase 3 OASIZ-301 trial, improving ESSDAI score in moderate-to-severe systemic Sjögren's disease.
Two-year data from the open-label extension show sustained ACR and MDA response rates for the TYK2 inhibitor in active psoriatic arthritis.
Oberlin outlines what dermatologists should weigh, beyond APEX's radiographic data, when selecting a biologic for PsA.
Beeline Medicines reported positive topline data meeting primary SRI-4 endpoint at week 48 across all 3 doses in systemic lupus erythematosus.
In a large real-world PsA cohort, higher BMI reduced the odds of minimal disease activity, especially with TNF inhibitors other than infliximab.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
Ruderman discusses how Northwestern's joint dermatology-rheumatology clinic shapes diagnosis and treatment of psoriatic disease.
Advertisement
Advertisement